PharmaCieloPCLOF +3.23% Debt-to-EBITDA is 4.32 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, PharmaCielo ranks worse than 99.27% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PharmaCielo's Debt-to-EBITDA or its related term are showing as below:
PCLOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.5 Med: -0.34 Max: 94.18
Current: 94.18
During the past 7 years, the highest Debt-to-EBITDA Ratio of PharmaCielo was 94.18. The lowest was -1.50. And the median was -0.34.
PCLOF's Debt-to-EBITDA is ranked worse than 99.27% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.66
vs PCLOF: 94.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PharmaCielo Debt-to-EBITDA Related Terms
PharmaCielo Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PharmaCielo's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmaCielo's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
PharmaCielo (PCLOF) has a Debt-to-EBITDA of 4.32 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCielo. According to the industry distribution chart, PharmaCielo ranks #680 out of 685 companies in the Drug Manufacturers industry, placing it in the top 99.3%.
Is PharmaCielo's Debt-to-EBITDA too high?
PharmaCielo's current Debt-to-EBITDA is 4.32. The Drug Manufacturers industry median Debt-to-EBITDA is 1.66. PharmaCielo's value of 4.32 is 160.2% above this industry median. Based on the distribution chart, PharmaCielo ranks #680 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #680 out of 685 companies for Debt-to-EBITDA. This places PharmaCielo in the lower half of its industry. The industry median Debt-to-EBITDA is 1.66. PharmaCielo's value of 4.32 is 160.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current Debt-to-EBITDA of 4.32 is 160.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PharmaCielo. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current Debt-to-EBITDA is 4.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.11, compared to a current price of $0.05 — trading 55% below its estimated fair value. The current Debt-to-EBITDA is 4.32 and 160.2% above the Drug Manufacturers industry median of 1.66. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Debt-to-EBITDA is 4.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 